| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 4, 2016Encouraging Early Outcomes from Rigorously Designed Study Set the Stage for IDE
DUBLIN and CHICAGO - April 4, 2016 - Medtronic plc (NYSE: MDT) today announced first-ever clinical data on the Harmony(TM) Transcatheter Pulmonary Valve (TPV) from its early feasibility study,...
-
Apr 3, 2016Medtronic Announces Early Data and Completes Enrollment in CE Mark Cohort in Drug-Filled Stent TrialRevElution Trial with Next-Gen Polymer-Free Stent Continues to Show Excellent Rapid Healing and Controlled Drug Delivery at ACC.16
DUBLIN and CHICAGO - April 3, 2016 - Medtronic plc (NYSE: MDT) announced new clinical data today from one of the endpoints in the RevElution Trial for its novel, next-generation Drug-Filled Stent...
-
Apr 2, 2016New Sub-study at ACC.16 from the CoreValve U.S. High Risk Trial Shows Exceptional Valve Performance for the Self-Expanding Transcatheter Heart Valve at Two Years
DUBLIN and CHICAGO - April 2, 2016 - Medtronic plc (NYSE: MDT) today unveiled new clinical data on the self-expanding CoreValve® System from the High Risk Study of the CoreValve U.S. Pivotal...
-
Mar 31, 2016
DUBLIN - March 31, 2016 - Medtronic plc (NYSE: MDT) today announced that the first patients were enrolled in the expanded indication trial for the CoreValve® Evolut® R System, the first and only...
-
Mar 31, 2016
DUBLIN - March 31, 2016 - Medtronic plc (the "Company") (NYSE: MDT) today announced the commencement of a cash tender offer (the "Tender Offer") by its wholly-owned subsidiaries, Medtronic, Inc....